Latest News-Jiangsu Alphamab Biopharmaceuticals Co.,Ltd Mediaroom_Page

Alphamab Oncology to Present Clinical Data of KN026 Combined with KN046 in HER2-positive Solid Tumors at AACR 2022

SUZHOU, China, March 9, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2022-03-09 09:14 2164

Alphamab Oncology Announced Publication of Clinical Results of KN026 in HER2-positive Breast Cancer in Clinical Cancer Research

SUZHOU, China, Feb. 24, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announcedClini...

2022-02-24 09:41 2692

Alphamab Oncology Announced IND Approval of PD-L1/OX40 Bispecific Antibody KN052

SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, tha...

2022-02-11 09:31 3406

Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046

* Interim analysis expected in the second quarter of 2022 SUZHOU, China, Jan. 13, 2022 /PRNewswir...

2022-01-13 10:46 3183

IND Approved for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer

SUZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharma...

2022-01-05 11:49 4497

Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046

SUZHOU, China, Dec. 23, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced dosi...

2021-12-23 09:13 3059

Posters Highlighting clinical data of KN026 presented at SABCS 2021

SUZHOU, China, Dec. 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharma...

2021-12-09 12:20 2243

IND Application for Phase 3 Registration Study of KN046 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer was Approved by CDE

SUZHOU, China, Nov. 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2021-11-24 09:35 2314

Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC

SUZHOU, China, Oct. 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, a p...

2021-10-29 09:36 2350

IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE

SUZHOU, China, Oct. 21, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharm...

2021-10-21 10:31 2387

Alphamab Oncology Completed Enrollment in the First Pivotal Phase III Clinical Study of the Bispecific Antibody KN046

* ENREACH-LUNG-01 is a multi-center, randomized, double-blind, placebo-controlled phase III clini...

2021-10-18 10:19 2323

Alphamab Oncology Reports 2021 Interim Results and Business Highlights

SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), announced the...

2021-08-30 10:51 3795

Alphamab Oncology and CSPC Achieved an Licensing Cooperation on Anti-HER2 Bispecific Antibody KN026 in Mainland China

SUZHOU, China, Aug. 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced toda...

2021-08-24 15:08 2497

Subcutaneously Injected PD-L1 Antibody Envafolimab (KN035) Obtained Its Second Orphan Drug Designation From The U.S. FDA

SUZHOU, China, June 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the ...

2021-06-30 08:55 8684

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021

SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data ...

2021-06-07 10:11 6605

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021

* KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical...

2021-06-07 10:10 6205

Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021

* As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in th...

2021-06-07 09:53 5779

Poster to Highlight ENVASARC Pivotal Trial of Envafolimab (KN035) will be presented at the 2021 ASCO Annual Meeting

SUZHOU, China, May 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the s...

2021-05-24 08:54 5746

Alphamab Oncology to Present Multiple Clinical Research Data at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021)

SUZHOU, China, May 20, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, data...

2021-05-20 09:34 8746

Alphamab announced PD-L1/CTLA-4 bispecific antibody KN046 will enter new Phase II clinical trial in combination with Pfizer's Inlyta® (axitinib)

SUZHOU, China, April 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced that...

2021-04-29 08:00 4682